The estimated Net Worth of Brian De Schuytner is at least $1.01 Million dollars as of 13 January 2024. Mr. Schuytner owns over 26,458 units of Mersana Therapeutics Inc stock worth over $112,993 and over the last 5 years he sold MRSN stock worth over $0. In addition, he makes $895,573 as Senior Vice President - Finance and Product Strategy at Mersana Therapeutics Inc.
Brian has made over 4 trades of the Mersana Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 26,458 units of MRSN stock worth $46,831 on 13 January 2024.
The largest trade he's ever made was exercising 26,458 units of Mersana Therapeutics Inc stock on 13 January 2024 worth over $46,831. On average, Brian trades about 8,155 units every 156 days since 2019. As of 13 January 2024 he still owns at least 63,838 units of Mersana Therapeutics Inc stock.
You can see the complete history of Mr. Schuytner stock trades at the bottom of the page.
Brian DeSchuytner serves as Senior Vice President - Finance and Product Strategy of the Company. Previously, Mr. DeSchuytner worked at Tesaro as Vice President, ZEJULA Commercial from January 2017 to June 2019. Prior to that, he held successively senior roles at Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals focused on oncology, from June 2009 to January 2017. He received a B.A. in Biophysical Chemistry from Dartmouth College and an M.B.A., concentrating in Finance and Health Care Management, from the Wharton School of the University of Pennsylvania.
As the Senior Vice President - Finance and Product Strategy of Mersana Therapeutics Inc, the total compensation of Brian DeSchuytner at Mersana Therapeutics Inc is $895,573. There are 3 executives at Mersana Therapeutics Inc getting paid more, with Anna Protopapas having the highest compensation of $1,739,800.
Brian DeSchuytner is 42, he's been the Senior Vice President - Finance and Product Strategy of Mersana Therapeutics Inc since 2019. There are 20 older and no younger executives at Mersana Therapeutics Inc. The oldest executive at Mersana Therapeutics Inc is Lawrence Alleva, 70, who is the Independent Director.
Brian's mailing address filed with the SEC is C/O MERSANA THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.
Over the last 7 years, insiders at Mersana Therapeutics Inc have traded over $1,068,087 worth of Mersana Therapeutics Inc stock and bought 26,457,775 units worth $226,822,416 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Mersana Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $534,621. The most recent stock trade was executed by Anna Protopapas on 13 January 2024, trading 86,958 units of MRSN stock currently worth $153,916.
mersana is rewriting the rules for immunoconjugate therapies by leveraging our fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives. our fleximer platform allows us to custom design an adc with specific properties to overcome limitations of current adc approaches and increase the drug’s chances of effectively attacking a particular cancer. we engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, mersana’s adc therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.
Mersana Therapeutics Inc executives and other stock owners filed with the SEC include: